A Phase 2/3 interventional study of fexofenadine/Allegra (M016455) in Atopic Dermatitis, sponsored by Sanofi. Completed at 13 sites in Japan. Open to participants aged 6 Months to 11 Years. Per ClinicalTrials.gov, last updated 2013-10-16.
Sponsored by Sanofi · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Dermatitis, Atopic by Sanofi — 5 open to participants now, 16 under way, 4 of them phase 3. Dermatitis, Atopic · Sanofi.
Among the 43 studies in Dermatitis, Atopic by Sanofi, this one is the 15th largest by enrollment of the 28 interventional ones that give a count, is the only one that started in 2010, is one of 2 in phase 2/3, and was the 2nd registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →5 of the 43 studies in Dermatitis, Atopic by Sanofi are open now, in 10 countries. Recruiting first, the newest first:
Sanofi · Sites in Qatar, Saudi Arabia, United Arab Emirates
Ages 12+
Sanofi · Sites in United States, Canada, China and 6 more countries
Ages 12+
Sanofi · Sites in Italy
Ages 6 mo–17 yrs
Sanofi
Ages 12+
Sanofi
Ages 18+
By country, each count listing its studies:
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 6 Months to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 10 · Phase 4 8
First in 2006; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 112 across the 28 interventional studies, 266 across the 15 observational. Of the 26 that completed or were terminated, 9 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
6 of the studies in Dermatitis, Atopic by Sanofi that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06241118Phase 3SanofiA Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor | 2027-09-30 |
| NCT07905547SanofiA Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic Dermatitis | 2027-02-07 |
| NCT03992417SanofiObservational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD) | 2027-03-31 |
| NCT05983068SanofiA Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis | 2027-04-29 |
| NCT06837454SanofiFrench Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (AD) | 2027-05-13 |
Add all 6 to your calendar (.ics) → With an account.
Among the 43 studies in Dermatitis, Atopic by Sanofi, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To evaluate safety (4 weeks)
Secondary Objectives:
The study consists of four phases: up to 9-day screening phase, main 4-week treatment phase, up-to 8-week extension phase, and up-to 5-day post-treatment phase.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Patients between 6 months and 2 years old - Type: Experimental
Drug: fexofenadine/Allegra (M016455)
Patients between 2 and 11 years (and under 10.5 kg)
Drug: fexofenadine/Allegra (M016455)
Patients between 2 and 11 years (and over 10.5 kg)
Drug: fexofenadine/Allegra (M016455)
Drug page: Fexofenadine
Pharmaceutical form:dry syrup formulation to be suspended in water Route of administration: oral
Number of patients with adverse events
Time frame: 4 weeks
The number of clinically significant abnormalities for laboratory findings
Time frame: 4 weeks
Number of patients with adverse events
Time frame: 12 weeks
The number of clinically significant abnormalities for laboratory findings
Time frame: 12 weeks
Changes from baseline in main itching scores on patient diary
Time frame: 4 weeks
Changes from baseline in pruritus intensity scores assessed by investigator or subinvestigator
Time frame: week 2 and 4
Pharmacokinetic parameters of fexofenadine at steady state; AUC
Time frame: week 4 and 12
The record gives a start of Nov 2010, a primary completion of Jul 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fexofenadine